The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Amy Luckenbaugh discussing the durability of nadofaragene firadenovec response in participants with BCG unresponsive non-muscle invasive disease. Nadofaragene firadenovec is an intravesical gene therapy for BCG-unresponsive non–muscle invasive bladder cancer with CIS with/without papillary tumors (±. Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA/ SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2 Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. This gene makes a protein called interferon alfa-2b, which activates the immune system to fight cancer cells. How do I take it? Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes Adstiladrin side effects, interactions and indications. Adstiladrin (Nadofaragene Firadenovec-vncg) represents a significant advancement in the treatment of certain types of bladder cancer. This innovative gene therapy is designed to address high-risk, non-muscle invasive bladder cancer (NMIBC) that has not responded to standard Bacillus Calmette-Guérin (BCG) therapy. Understanding its mechanism, proper administration, and potential side effects. For the treatment of High-grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer. STIL EFFECTIVE out to 5 years In a clinical study, ADSTILADRIN was tested in people with high-risk NMIBC whose cancer did not respond to BCG. They had checkups over 5 years to measure how well treatment helped them keep their bladder, avoid progressing to MIBC, and remain free of high-grade bladder cancer signs. Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors. This medicine is to be used only by or under the direct supervision of a doctor. Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state. First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the first and only FDA-approved intravesical gene therapy.